Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psychiatric drugs
Biotech
FDA hits Newron schizophrenia ph. 3 trial with hold after death
The patient's death was deemed unrelated to treatment, Newron said, and sudden death is more common in people with schizophrenia.
Darren Incorvaia
Apr 29, 2026 2:50pm
Big Pharma-backed MapLight plots IPO
Sep 22, 2025 1:57pm
AbbVie inks $1.2B deal to buy Gilgamesh's psychedelic program
Aug 25, 2025 9:42am
Arialys presents promising data for IgG1 antibody treatment
Jun 20, 2025 5:02am
AbbVie makes Richter richer, paying $25M to form discovery pact
Oct 25, 2024 7:55am
AbbVie pens $2B-plus neuro pact with Gilgamesh
May 13, 2024 5:57pm
